Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70137 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Stefan Wissel und 5 weiteren Autor:innen. Beteiligte Einrichtung: HWI Pharma Services GmbH, Rülzheim, Germany. Hauptthemen laut MEDLINE: Ivermectin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nasal epithelium is the site of infection for SARS‐CoV2 viruses, with interactions of the viral spike protein with the ACE2 receptor of the host cell. Molecular docking studies have shown that ivermectin shields the spike protein and thereby prevents binding to ACE2. Nasal application of high doses of ivermectin could be the right therapeutic approach in the treatment and prevention of COVID‐19. Tolerability, safety, and pharmacokinetics of ivermectin, administered nasally as 5% microsuspension (F004), were investigated in a randomized, double‐blind, parallel‐groups, placebo‐controlled phase 1 study in 28 healthy adults. Bioavailability of a single dose of 14 mg ivermectin was determined with AUC 0–t T of 1701.1 ng/mL h (AUC 0–∞ of 2382.7 ng/mL h, calculated), C max of 96.2 ng/mL, T max of 4.4 h, and T 1/2 of 59.9 h. Following 42 mg/day multiple dose (3 × 14 mg every 6 h) administered nasally over 5 days, AUC 0‐∞ of 2194.4 ng/mL h was analyzed, and 96% of ivermectin concentrations were still measurable 12 h after the last dose. F004 was safe in this study and well‐tolerated. Nine (F004 group) and three (placebo group) of 28 subjects reported 14 symptoms, including a few systemic but mainly local nasal adverse events (AE). The number of subjects reporting AE decreased continuously after both F004 and placebo treatment. All subjects recovered fully with no AE recorded at the end of the study. Nasal examination showed stable patterns of nasal mucosal grading, mucosal bleeding, and crusting of the mucosa. Nasally administered ivermectin is well tolerated in high concentrations and could provide systemic therapeutic benefits in addition to local effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HWI Pharma Services GmbH, Rülzheim, Germany.
- Dr. Riethmüller M/R/S GmbH, Frankfurt am Main, Germany.
- Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Bonn, Germany.
Zitieren
APA
Wissel, S., Wissel, P., Rischer, M., Häberlein, F., Riethmüller-Winzen, H., & Häberlein, H. (2026). Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70137
Vancouver
Wissel S, Wissel P, Rischer M, Häberlein F, Riethmüller-Winzen H, Häberlein H. Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70137
BibTeX
@article{Wissel2026,
author = {Wissel, Stefan and Wissel, Philipp and Rischer, Matthias and Häberlein, Felix and Riethmüller-Winzen, Hilde and Häberlein, Hanns},
title = {Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70137}
}
EUVIMED